News
BMS carves out a neoadjuvant niche for Opdivo in NSCLC
Bristol-Myers Squibb's Opdivo has been playing second fiddle to Merck & Co's Keytruda in the non-small cell lung cancer (NSCLC) market for years, but now it has a chance to take the lim
